WT:Gnas fl/fl [saline] p = 0.0341
Eligibility for treatment starts at a BMI of 27, supporting not just weight loss but the adoption of healthier habits
The remaining $1,270 covers patent licensing, marketing expenditure, PBM rebate structures, and shareholder profit expectations built into pharmaceutical pricing models designed around third-party payers, not cash customers
Some diabetes medications, including sulfonylureas and insulin, may interact with GLP-1 medications and increase the risk of hypoglycemia
STEP UP: In adults with obesity, along with diet and exercise, Wegovy HD (semaglutide) injection 7.2 mg: Designed to deliver greater weight-loss results than the Wegovy you know 1 Mean change in body weight (%) from week 0 to week 72 1 Co-primary end point 1 : Percentage of patients achieving 5% weight loss at 72 weeks: 88.7% of patients with Wegovy vs 38.3% with placebo HD Treatment regimen estimand: This estimand is based on the intention-to-treat principle and was used as the primary analysis method *Co-primary end point: % change in body weight for Wegovy HD vs placebo